

Richard Day

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5289266/publications.pdf>

Version: 2024-02-01

474
papers

21,347
citations

18436

62
h-index

12910

131
g-index

492
all docs

492
docs citations

492
times ranked

18689
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1520-1528.	13.9	3,651
2	Clinical Pharmacokinetics of Metformin. <i>Clinical Pharmacokinetics</i> , 2011, 50, 81-98.	1.6	910
3	Nonsteroidal Antiinflammatory Drugs " Differences and Similarities. <i>New England Journal of Medicine</i> , 1991, 324, 1716-1725.	13.9	745
4	Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis. <i>Annals of Internal Medicine</i> , 1994, 121, 289.	2.0	595
5	Association of Interruptions With an Increased Risk and Severity of Medication Administration Errors. <i>Archives of Internal Medicine</i> , 2010, 170, 683.	4.3	565
6	The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. <i>Inflammopharmacology</i> , 2013, 21, 201-232.	1.9	440
7	Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. <i>BMJ, The</i> , 2015, 350, h1225-h1225.	3.0	416
8	Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. <i>Clinical Pharmacokinetics</i> , 2000, 38, 225-242.	1.6	358
9	CareTrack: assessing the appropriateness of health care delivery in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 100-105.	0.8	327
10	Effects of Allopurinol on the Progression of Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 2504-2513.	13.9	281
11	Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain. <i>JAMA Internal Medicine</i> , 2016, 176, 958.	2.6	258
12	Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2014, 384, 1586-1596.	6.3	255
13	Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 592-599.	1.1	246
14	A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout. <i>Drug Safety</i> , 2008, 31, 643-665.	1.4	243
15	Bioavailability of hydroxychloroquine tablets in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 771-779.	1.1	235
16	Does Computerized Provider Order Entry Reduce Prescribing Errors for Hospital Inpatients? A Systematic Review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 613-623.	2.2	226
17	Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. <i>Lancet, The</i> , 2007, 370, 1638-1643.	6.3	203
18	Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 425-432.	1.1	200

#	ARTICLE	IF	CITATIONS
19	The stereoselective uptake of ibuprofen enantiomers into adipose tissue. <i>Biochemical Pharmacology</i> , 1986, 35, 3403-3405.	2.0	168
20	Trial of Pregabalin for Acute and Chronic Sciatica. <i>New England Journal of Medicine</i> , 2017, 376, 1111-1120.	13.9	164
21	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2157-2164.	0.5	160
22	A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 303-313.	1.1	157
23	Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. <i>Clinical Pharmacokinetics</i> , 2007, 46, 623-644.	1.6	153
24	Effects of Two Commercial Electronic Prescribing Systems on Prescribing Error Rates in Hospital In-Patients: A Before and After Study. <i>PLoS Medicine</i> , 2012, 9, e1001164.	3.9	153
25	Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 851-858.	0.5	152
26	Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012. <i>Drug Safety</i> , 2013, 36, 953-980.	1.4	145
27	Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1269-1278.	0.5	143
28	Adverse reactions to TNF- α inhibitors in rheumatoid arthritis. <i>Lancet, The</i> , 2002, 359, 540-541.	6.3	141
29	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. <i>Nature Reviews Rheumatology</i> , 2016, 12, 235-242.	3.5	139
30	Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 4497-4501.	3.3	137
31	Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs ¹ . <i>Biochemical Pharmacology</i> , 1989, 38, 4389-4395.	2.0	120
32	Tolerability of Paracetamol. <i>Drug Safety</i> , 2005, 28, 227-240.	1.4	120
33	What are incident reports telling us? A comparative study at two Australian hospitals of medication errors identified at audit, detected by staff and reported to an incident system. <i>International Journal for Quality in Health Care</i> , 2015, 27, 1-9.	0.9	111
34	Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. <i>British Journal of Pharmacology</i> , 2008, 154, 1691-1700.	2.7	109
35	Predicting 7-day, 30-day and 60-day all-cause unplanned readmission: a case study of a Sydney hospital. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 1.	1.5	106
36	Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 410-420.	2.3	104

#	ARTICLE	IF	CITATIONS
37	Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers.. British Journal of Clinical Pharmacology, 1989, 28, 695-702.	1.1	104
38	Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function. Clinical Pharmacokinetics, 2013, 52, 373-384.	1.6	98
39	Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2018, 74, 15-27.	0.8	97
40	Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clinical Microbiology and Infection, 2019, 25, 1286.e1-1286.e7.	2.8	96
41	Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1982, 31, 733-740.	2.3	91
42	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Clinical Pharmacology and Therapeutics, 2006, 80, 75-84.	2.3	86
43	Real-time prediction of mortality, readmission, and length of stay using electronic health record data. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 553-561.	2.2	85
44	Anabolic-androgenic steroids: medical assessment of present, past and potential users. Medical Journal of Australia, 2000, 173, 323-327.	0.8	84
45	A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. Journal of Rheumatology, 2004, 31, 775-82.	1.0	84
46	Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users. Clinical Pharmacokinetics, 1997, 33, 344-400.	1.6	83
47	The safety of electronic prescribing: manifestations, mechanisms, and rates of system-related errors associated with two commercial systems in hospitals. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 1159-1167.	2.2	83
48	Effects of Budesonide and Fluticasone on 24-Hour Plasma Cortisol. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1746-1751.	2.5	82
49	Effects of St John's wort and <i>CYP2C9</i> genotype on the pharmacokinetics and pharmacodynamics of glimepiride. British Journal of Pharmacology, 2008, 153, 1579-1586.	2.7	82
50	Paracetamol versus placebo for knee and hip osteoarthritis. The Cochrane Library, 2019, 2019, CD013273.	1.5	82
51	Clinical pharmacology of non-steroidal anti-inflammatory drugs. , 1987, 33, 383-433.		80
52	The effectiveness of information technology to improve antimicrobial prescribing in hospitals: A systematic review and meta-analysis. International Journal of Medical Informatics, 2016, 92, 15-34.	1.6	78
53	The death of a healthy volunteer in a human research project: implications for Australian clinical research. Medical Journal of Australia, 1998, 168, 449-451.	0.8	77
54	Liquid Chromatographic Determination and Plasma Concentration Profile of Optical Isomers of Ibuprofen in Humans. Journal of Pharmaceutical Sciences, 1984, 73, 1542-1544.	1.6	75

#	ARTICLE	IF	CITATIONS
55	THE ONCOGENICITY OF CHLORAMBUCIL IN RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1988, 27, 44-47.	0.9	75
56	THE PHARMACOKINETICS, SAFETY AND ENDOCRINE EFFECTS OF AUTHENTIC BIOSYNTHETIC HUMAN GROWTH HORMONE IN NORMAL SUBJECTS. <i>Clinical Endocrinology</i> , 1989, 30, 335-345.	1.2	75
57	The Problems and Pitfalls of NSAID Therapy in the Elderly (Part I)1. <i>Drugs and Aging</i> , 1991, 1, 130-143.	1.3	74
58	The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. <i>Drug Safety</i> , 2013, 36, 733-746.	1.4	69
59	Correction. <i>British Journal of Sports Medicine</i> , 2014, 48, 1396-1396.	3.1	69
60	Pharmacokinetics of Nonsteroidal Anti-Inflammatory Drugs in Synovial Fluid. <i>Clinical Pharmacokinetics</i> , 1999, 36, 191-210.	1.6	67
61	An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 2006, 14, 859-866.	0.6	63
62	Stereoselective disposition of ibuprofen enantiomers in synovial fluid. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 480-487.	2.3	62
63	Metformin therapy in patients with chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 963-965.	2.2	61
64	Variability in Response to NSAIDs. <i>Drugs</i> , 1988, 36, 643-651.	4.9	60
65	Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugsâ€™ II Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters. <i>Biochemical Pharmacology</i> , 1991, 42, 1905-1911.	2.0	59
66	Errors and electronic prescribing: a controlled laboratory study to examine task complexity and interruption effects. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 575-583.	2.2	57
67	Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis. Support for the concept of "responders" and "nonresponders". <i>Arthritis and Rheumatism</i> , 1997, 40, 1944-1954.	6.7	56
68	Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout. <i>Journal of Rheumatology</i> , 2011, 38, 904-910.	1.0	56
69	Use of colchicine in pregnancy: a systematic review and meta-analysis. <i>Rheumatology</i> , 2018, 57, 382-387.	0.9	56
70	The influence of computerized decision support on prescribing during ward-rounds: are the decision-makers targeted?. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 754-759.	2.2	55
71	Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. <i>Arthritis Research and Therapy</i> , 2015, 17, 288.	1.6	54
72	Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 299-304.	1.1	53

#	ARTICLE	IF	CITATIONS
73	Barriers to Care in Gout: From Prescriber to Patient. <i>Journal of Rheumatology</i> , 2016, 43, 144-149.	1.0	53
74	Automation bias in electronic prescribing. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 28.	1.5	53
75	Stereoselective disposition of ibuprofen and flurbiprofen in rats. <i>Chirality</i> , 1990, 2, 134-140.	1.3	52
76	Metabolic sequelae of β -blocker therapy: weighing in on the obesity epidemic?. <i>International Journal of Obesity</i> , 2011, 35, 1395-1403.	1.6	52
77	Alert override as a habitual behavior – a new perspective on a persistent problem. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 409-412.	2.2	51
78	Enhanced metabolism of mexiletine after phenytoin administration.. <i>British Journal of Clinical Pharmacology</i> , 1982, 14, 219-223.	1.1	50
79	Effect of μ -opioids morphine and buprenorphine on the development of adjuvant arthritis in rats. <i>Inflammation Research</i> , 1996, 45, 557-563.	1.6	50
80	Antimalarials in rheumatic diseases. <i>Bailliere's Clinical Rheumatology</i> , 1990, 4, 467-489.	1.0	49
81	Overdose with chloral hydrate: a pharmacological and therapeutic review. <i>Medical Journal of Australia</i> , 1988, 149, 686-688.	0.8	48
82	Adverse Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). <i>Drug Safety</i> , 1993, 8, 99-127.	1.4	48
83	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	1.5	48
84	Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. <i>Journal of Rheumatology</i> , 1993, 20, 1874-9.	1.0	48
85	Towards the delivery of appropriate health care in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 78-81.	0.8	45
86	Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 423-428.	1.1	44
87	Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?. <i>Internal Medicine Journal</i> , 2012, 42, 411-416.	0.5	44
88	The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. <i>Medical Journal of Australia</i> , 2021, 214, 324-331.	0.8	44
89	Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis—a prospective, dose ranging study. <i>Journal of Rheumatology</i> , 2000, 27, 1656-60.	1.0	44
90	Comparative Analgesia, Cardiovascular and Renal Effects of Celecoxib, Rofecoxib and Acetaminophen (Paracetamol). <i>Current Pharmaceutical Design</i> , 2002, 8, 1063-1075.	0.9	43

#	ARTICLE	IF	CITATIONS
91	Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. <i>Medical Journal of Australia</i> , 2005, 182, 557-560.	0.8	43
92	Bringing cohort studies to the bedside: framework for a "green button"™ to support clinical decision-making. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 191-197.	0.6	43
93	Identification of Products from Oxidation of Uric Acid Induced by Hydroxyl Radicals. <i>Free Radical Research Communications</i> , 1993, 18, 337-351.	1.8	42
94	A Model Averaging/Selection Approach Improves the Predictive Performance of Model-Informed Precision Dosing: Vancomycin as a Case Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 175-183.	2.3	42
95	The Problems and Pitfalls of NSAID Therapy in the Elderly (Part II)1. <i>Drugs and Aging</i> , 1991, 1, 212-227.	1.3	41
96	Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. <i>Medical Journal of Australia</i> , 1997, 167, 134-136.	0.8	41
97	Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. <i>BMJ, The</i> , 2021, 374, n1446.	3.0	41
98	Variations in response to non-steroidal anti-inflammatory drugs.. <i>British Journal of Clinical Pharmacology</i> , 1987, 23, 655-658.	1.1	40
99	Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β -oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac. <i>Biochemical Pharmacology</i> , 1999, 57, 837-844.	2.0	40
100	Drug checking to improve monitoring of new psychoactive substances in Australia. <i>Medical Journal of Australia</i> , 2016, 204, 144-145.	0.8	40
101	Open-Label Extension Studies. <i>Drug Safety</i> , 2007, 30, 93-105.	1.4	39
102	Antioxidant activity of propylthiouracil. <i>Biochemical Pharmacology</i> , 1992, 43, 439-444.	2.0	38
103	The effect of the enantiomers of ibuprofen and flurbiprofen on the β -oxidation of palmitate in the rat. <i>Chirality</i> , 1992, 4, 137-141.	1.3	38
104	Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. <i>Internal Medicine Journal</i> , 2006, 36, 571-578.	0.5	38
105	Formoterol, a highly β 2-selective agonist, increases energy expenditure and fat utilisation in men. <i>International Journal of Obesity</i> , 2013, 37, 593-597.	1.6	38
106	Patients'™ use of mobile health applications: what general practitioners think. <i>Family Practice</i> , 2019, 36, 214-218.	0.8	38
107	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. <i>Lancet Rheumatology, The</i> , 2019, 1, e220-e228.	2.2	38
108	Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 45.	1.0	37

#	ARTICLE	IF	CITATIONS
109	Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.. British Journal of Clinical Pharmacology, 1993, 36, 78-81.	1.1	36
110	BIOAVAILABILITY OF HYDROXYCHLOROQUINE TABLETS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 1994, 33, 235-239.	0.9	36
111	Life-threatening drug interactions: what the physician needs to know. Internal Medicine Journal, 2017, 47, 501-512.	0.5	36
112	Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. BMJ, The, 2021, 372, n104.	3.0	36
113	Anti-rheumatic Drug Interactions. Clinics in Rheumatic Diseases, 1984, 10, 251-275.	1.2	36
114	Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994 A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Medical Journal of Australia, 1996, 164, 589-592.	0.8	35
115	Response to Expression of Concern Regarding VIGOR Study. New England Journal of Medicine, 2006, 354, 1196-1199.	13.9	35
116	Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2010, 69, 508-515.	1.1	35
117	Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. Lancet, The, 2017, 389, 1268-1272.	6.3	35
118	Bioavailability of Hydroxychloroquine Tablets Assessed with Deconvolution Techniques. Journal of Pharmaceutical Sciences, 1992, 81, 155-159.	1.6	34
119	Potentially inappropriate medications (<scp>PIMs</scp>) in older hospital inpatients: Prevalence, contribution to hospital admission and documentation of rationale for continuation. Australasian Journal on Ageing, 2016, 35, 262-265.	0.4	34
120	Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clinical Pharmacokinetics, 2017, 56, 459-475.	1.6	34
121	Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid??in Healthy Subjects. Clinical Pharmacokinetics, 2008, 47, 111-118.	1.6	33
122	Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. British Journal of Clinical Pharmacology, 2013, 76, 932-938.	1.1	33
123	Mobile applications to enhance self-management of gout. International Journal of Medical Informatics, 2016, 94, 67-74.	1.6	33
124	Pharmacokinetics of non-steroidal anti-inflammatory drugs. Bailliere's Clinical Rheumatology, 1988, 2, 363-393.	1.0	32
125	Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.. British Journal of Clinical Pharmacology, 1988, 26, 429-434.	1.1	32
126	Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Research and Therapy, 2012, 14, R189.	1.6	32

#	ARTICLE	IF	CITATIONS
127	PACE - The first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskeletal Disorders, 2010, 11, 169.	0.8	31
128	Xanthine oxidoreductase and its inhibitors: relevance for gout. Clinical Science, 2016, 130, 2167-2180.	1.8	31
129	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. PLoS ONE, 2016, 11, e0147939.	1.1	31
130	INTERACTIONS BETWEEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND ANTIHYPERTENSIVES AND DIURETICS. Australian and New Zealand Journal of Medicine, 1986, 16, 537-546.	0.5	30
131	Preventing acute gout when starting allopurinol therapy. Medical Journal of Australia, 1993, 159, 182-184.	0.8	30
132	Drug Interactions of Clinical Importance An Updated Guide. Drug Safety, 1995, 12, 393-452.	1.4	30
133	Hydroxychloroquine relative bioavailability: within subject reproducibility. British Journal of Clinical Pharmacology, 1996, 41, 244-246.	1.1	30
134	A Risk-Benefit Assessment of Paracetamol (Acetaminophen) Combined with Caffeine. Pain Medicine, 2010, 11, 951-965.	0.9	30
135	Failure to utilize functions of an electronic prescribing system and the subsequent generation of "technically preventable" computerized alerts. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 1003-1010.	2.2	30
136	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Annals of the Rheumatic Diseases, 2016, 75, 1363-1366.	0.5	30
137	Risks and Benefits of Drugs Used in the Management and Prevention of Gout. Drug Safety, 1994, 11, 252-258.	1.4	29
138	Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs. Inflammopharmacology, 1999, 7, 255-263.	1.9	29
139	Evaluating medicines: let's use all the evidence. Medical Journal of Australia, 2007, 186, 249-252.	0.8	29
140	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clinical Pharmacokinetics, 2020, 59, 1357-1392.	1.6	29
141	Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality, 1994, 6, 355-359.	1.3	28
142	The economic burden of guideline-recommended first line care for acute low back pain. European Spine Journal, 2018, 27, 109-116.	1.0	27
143	Anti-rheumatic drug interactions. Clinics in Rheumatic Diseases, 1984, 10, 251-75.	1.2	27
144	"It looks after me". How older patients make decisions about analgesics for osteoarthritis. Arthritis Care and Research, 2011, 63, 1280-1286.	1.5	26

#	ARTICLE	IF	CITATIONS
145	The pharmacokinetics of oxypurinol in people with gout. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 477-489.	1.1	26
146	CareTrack: assessing the appropriateness of health care delivery in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 549-550.	0.8	25
147	The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 416-426.	1.1	25
148	Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. <i>Journal of Rheumatology</i> , 1995, 22, 2295-303.	1.0	25
149	Pharmacokinetics of Carprofen in Plasma and Synovial Fluid. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 635-643.	1.0	24
150	The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 221-227.	1.1	24
151	Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 551-561.	1.1	24
152	Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk. <i>Age and Ageing</i> , 2011, 40, 254-259.	0.7	24
153	CareTrack Australia: assessing the appropriateness of adult healthcare: protocol for a retrospective medical record review. <i>BMJ Open</i> , 2012, 2, e000665.	0.8	24
154	Redesign of computerized decision support to improve antimicrobial prescribing. <i>Applied Clinical Informatics</i> , 2017, 08, 949-963.	0.8	24
155	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. <i>Drug Safety</i> , 2020, 43, 1211-1221.	1.4	24
156	Audit and feedback of antibiotic use. <i>Applied Clinical Informatics</i> , 2013, 04, 583-595.	0.8	23
157	Cost-effectiveness analysis of a hospital electronic medication management system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 784-793.	2.2	23
158	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	1.1	23
159	Implementing large-system, value-based healthcare initiatives: a realist study protocol for seven natural experiments. <i>BMJ Open</i> , 2020, 10, e044049.	0.8	23
160	Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions. <i>Molecular Pharmacology</i> , 1991, 40, 613-8.	1.0	23
161	Drugs involved in self-poisoning: verification by toxicological analysis. <i>Medical Journal of Australia</i> , 1986, 144, 455-457.	0.8	22
162	Pethidine in emergency departments: promoting evidence-based prescribing. <i>Medical Journal of Australia</i> , 2005, 183, 129-133.	0.8	22

#	ARTICLE	IF	CITATIONS
163	FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. <i>Inflammopharmacology</i> , 2010, 18, 47-55.	1.9	22
164	An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β -lactam therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2171-2175.	1.3	22
165	The vascular effects of COX-2 selective inhibitors. <i>Australian Prescriber</i> , 2004, 27, 142-145.	0.5	22
166	Indicators for Drug and Therapeutics Committees. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 393-398.	1.1	21
167	The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 2.	2.2	21
168	Prioritising drug and therapeutics committee (DTC) decisions: a national survey. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 90-96.	1.4	21
169	Extreme β -Butyrolactone Overdose With Severe Metabolic Acidosis Requiring Hemodialysis. <i>Annals of Emergency Medicine</i> , 2011, 58, 83-85.	0.3	21
170	Diabetes Education: the Experiences of Young Adults with Type 1 Diabetes. <i>Diabetes Therapy</i> , 2014, 5, 299-321.	1.2	21
171	Allopurinol: insights from studies of dose-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 449-462.	1.5	21
172	Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 783.e7-783.e14.	2.8	21
173	Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 62.	2.5	21
174	Health Economic and Quality of Life Considerations in the Management of Pain. <i>Drugs</i> , 2003, 63, 43-46.	4.9	21
175	High-performance liquid chromatographic determination of a new anti-inflammatory agent, nabumetone, and its major metabolite in plasma using fluorimetric detection. <i>Biomedical Applications</i> , 1984, 336, 234-239.	1.7	20
176	Ties That Bind. <i>Archives of Internal Medicine</i> , 2005, 165, 2493.	4.3	20
177	Simultaneous Determination of Rofecoxib and Celecoxib in Human Plasma by High-Performance Liquid Chromatography. <i>Journal of Chromatographic Science</i> , 2005, 43, 351-354.	0.7	20
178	Optimizing Therapy With Allopurinol: Factors Limiting Hypouricemic Efficacy. <i>American Journal of the Medical Sciences</i> , 2008, 335, 219-226.	0.4	20
179	Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. <i>BMC Health Services Research</i> , 2012, 12, 248.	0.9	20
180	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. <i>Internal Medicine Journal</i> , 2013, 43, 547-553.	0.5	20

#	ARTICLE	IF	CITATIONS
181	Stepped-wedge cluster randomised controlled trial to assess the effectiveness of an electronic medication management system to reduce medication errors, adverse drug events and average length of stay at two paediatric hospitals: a study protocol. <i>BMJ Open</i> , 2016, 6, e011811.	0.8	20
182	Evaluation of an Enteric Coated Aspirin Preparation. <i>Australian and New Zealand Journal of Medicine</i> , 1976, 6, 45-50.	0.5	19
183	THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON ADENOSINE TRIPHOSPHATE CONTENT AND HISTAMINE RELEASE FROM RAT PERITONEAL CELL SUSPENSIONS RICH IN MAST CELLS. <i>British Journal of Pharmacology</i> , 1977, 59, 29-33.	2.7	19
184	Induction of Salicylic Acid Formation in Rheumatoid Arthritis Patients Treated with Salicylates. <i>Clinical Pharmacokinetics</i> , 1983, 8, 263-271.	1.6	19
185	Hydrogen peroxide modulation of the respiratory burst of human neutrophils. <i>Biochemical Pharmacology</i> , 1991, 41, 31-36.	2.0	19
186	An attempt to influence hypnotic and sedative drug use. <i>Medical Journal of Australia</i> , 1992, 156, 389-396.	0.8	19
187	The Position of Paracetamol in the World of Analgesics. <i>American Journal of Therapeutics</i> , 2000, 7, 51-54.	0.5	19
188	PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 213.	0.7	19
189	Junior doctors' prescribing work after-hours and the impact of computerized decision support. <i>International Journal of Medical Informatics</i> , 2013, 82, 980-986.	1.6	19
190	Pad use at the bedside: a tool for engaging patients in care processes during ward rounds?. <i>Internal Medicine Journal</i> , 2014, 44, 986-990.	0.5	19
191	Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1988, 15, 28-34.	1.0	19
192	Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. <i>Chirality</i> , 1994, 6, 360-364.	1.3	18
193	Severe carbon monoxide poisoning from waterpipe smoking: a public health concern. <i>Medical Journal of Australia</i> , 2015, 202, 446-447.	0.8	18
194	Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3293-3302.	1.3	18
195	Aspects of the Clinical Pharmacology of Non-steroidal Anti-inflammatory Drugs. <i>Clinics in Rheumatic Diseases</i> , 1984, 10, 229-249.	1.2	18
196	Pharmacokinetics Of Ibuprofen Enantiomers In Plasma And Suction Blister Fluid In Healthy Volunteers. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 787-790.	1.6	17
197	New Uses for Allopurinol. <i>Drugs</i> , 1994, 48, 339-344.	4.9	17
198	Utilization of allopurinol in the Australian community. <i>Internal Medicine Journal</i> , 2008, 38, 388-395.	0.5	17

#	ARTICLE	IF	CITATIONS
199	Can Predictors of Response to NSAIDs Be Identified in Patients With Acute Low Back Pain?. <i>Clinical Journal of Pain</i> , 2009, 25, 659-665.	0.8	17
200	The Role of Computerized Decision Support in Reducing Errors in Selecting Medicines for Prescription. <i>Drug Safety</i> , 2011, 34, 289-298.	1.4	17
201	The economic evaluation of personalised oncology medicines: ethical challenges. <i>Medical Journal of Australia</i> , 2013, 199, 471-473.	0.8	17
202	Individualising the dose of allopurinol in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2015-2026.	1.1	17
203	CareTrack. <i>Spine</i> , 2017, 42, E802-E809.	1.0	17
204	Associations between double-checking and medication administration errors: a direct observational study of paediatric inpatients. <i>BMJ Quality and Safety</i> , 2021, 30, 320-330.	1.8	17
205	6-MERCAPTOPYRIMIDINE-RELATED LEUCOPENIA AND IN VIVO XANTHINE OXIDASE ACTIVITY. <i>Lancet</i> , The, 1986, 328, 869-870.	6.3	16
206	Effect of food and various antacids on the absorption of tenoxicam.. <i>British Journal of Clinical Pharmacology</i> , 1987, 24, 323-328.	1.1	16
207	Dâ€penicillamine and Dâ€penicillamineâ€protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 511-517.	1.1	16
208	Implementing electronic medication management at an Australian teaching hospital. <i>Medical Journal of Australia</i> , 2011, 195, 498-502.	0.8	16
209	Shared decision-making: the perspectives of young adults with type 1 diabetes mellitus. <i>Patient Preference and Adherence</i> , 2014, 8, 423.	0.8	16
210	A time and motion study of junior doctor work patterns on the weekend: a potential contributor to the weekend effect?. <i>Internal Medicine Journal</i> , 2016, 46, 819-825.	0.5	16
211	A systems science perspective on the capacity for change in public hospitals. <i>Israel Journal of Health Policy Research</i> , 2017, 6, 16.	1.4	16
212	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 212-221.	2.3	16
213	Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4221-4229.	1.1	16
214	Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study. <i>Arthritis Research and Therapy</i> , 2021, 23, 160.	1.6	16
215	Long-Term Patterns of Online Evidence Retrieval Use in General Practice: A 12-Month Study. <i>Journal of Medical Internet Research</i> , 2008, 10, e6.	2.1	16
216	Nonâ€steroidal antiâ€inflammatory drugs. <i>Medical Journal of Australia</i> , 1995, 163, 155-158.	0.8	16

#	ARTICLE	IF	CITATIONS
217	A functional psychosis precipitated by quinidine. <i>Medical Journal of Australia</i> , 1990, 153, 47-49.	0.8	15
218	Analgesic efficacy of non-steroidal anti-inflammatory drugs in experimental pain in humans. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 417-425.	1.1	15
219	Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. <i>Internal Medicine Journal</i> , 2005, 35, 206-210.	0.5	15
220	Republished research: Non-steroidal anti-inflammatory drugs (NSAIDs). <i>British Journal of Sports Medicine</i> , 2013, 47, 1127-1127.	3.1	15
221	Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 800-814.	1.1	15
222	Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?. <i>Internal Medicine Journal</i> , 2015, 45, 55-62.	0.5	15
223	Barriers and facilitators of appropriate vancomycin use: prescribing context is key. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1523-1529.	0.8	15
224	Where to find information about drugs. <i>Australian Prescriber</i> , 2016, 39, 88-95.	0.5	15
225	The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. <i>Arthritis and Rheumatism</i> , 1991, 34, 751-760.	6.7	14
226	Absorption and <i>in vivo</i> dissolution of hydroxychloroquine in fed subjects assessed using deconvolution techniques. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 405-411.	1.1	14
227	The Application of Adverse Drug Reaction Data to Drug Choice Decisions Made by Pharmacy and Therapeutics Committees. <i>Drug Safety</i> , 1998, 18, 153-159.	1.4	14
228	A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenopausal women. <i>BMC Research Notes</i> , 2010, 3, 180.	0.6	14
229	A proposal for identifying the low renal uric acid clearance phenotype. <i>Arthritis Research and Therapy</i> , 2010, 12, 149.	1.6	14
230	PACE – the first placebo controlled trial of paracetamol for acute low back pain: statistical analysis plan. <i>Trials</i> , 2013, 14, 248.	0.7	14
231	Antifungal Use and Therapeutic Monitoring of Plasma Concentrations of Itraconazole in Heart and Lung Transplantation Patients. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 133-136.	1.0	14
232	Multidisciplinary diabetes team care: the experiences of young adults with type 1 diabetes. <i>Health Expectations</i> , 2015, 18, 1783-1796.	1.1	14
233	A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 981-990.	0.8	14
234	Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation. <i>Applied Clinical Informatics</i> , 2018, 09, 849-855.	0.8	14

#	ARTICLE	IF	CITATIONS
235	Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised dose recommendation software. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1215-1233.	1.1	14
236	Mode of action of non-steroidal anti-inflammatory drugs. <i>Medical Journal of Australia</i> , 1988, 148, 195-199.	0.8	14
237	Non-steroidal anti-inflammatory drug induced upper gastrointestinal haemorrhage and bleeding. <i>Medical Journal of Australia</i> , 1992, 157, 810-812.	0.8	14
238	Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis. <i>Medical Journal of Australia</i> , 2022, 216, 305-311.	0.8	14
239	The Effects of Enteric Coating of Aspirin Tablets on Occult Gastrointestinal Blood Loss. <i>Australian and New Zealand Journal of Medicine</i> , 1977, 7, 600-604.	0.5	13
240	High-Performance Liquid Chromatographic Analysis of Diflunisal in Plasma and Urine: Application to Pharmacokinetic Studies in Two Normal Volunteers. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1403-1405.	1.6	13
241	Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. <i>BMC Musculoskeletal Disorders</i> , 2005, 6, 57.	0.8	13
242	Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. <i>Internal Medicine Journal</i> , 2007, 37, 798-805.	0.5	13
243	Acute kidney injury due to crystalluria following acute valacyclovir overdose. <i>Kidney International</i> , 2011, 79, 574.	2.6	13
244	How clinical and research failures lead to suboptimal prescribing: the example of chronic gout. <i>BMJ: British Medical Journal</i> , 2011, 343, d7459-d7459.	2.4	13
245	Learning from Hackers: Open-Source Clinical Trials. <i>Science Translational Medicine</i> , 2012, 4, 132cm5.	5.8	13
246	Shedding light on junior doctors' work practices after hours. <i>Internal Medicine Journal</i> , 2013, 43, 1321-1326.	0.5	13
247	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227.	1.1	13
248	Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3077-3081.	2.0	13
249	Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. <i>BMC Family Practice</i> , 2018, 19, 54.	2.9	13
250	Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109036.	1.1	13
251	Stereoselective Disposition Basis for Variability in Response to NSAIDs. <i>Journal of Pharmaceutical Sciences</i> , 1985, 17, 119-126.		13
252	Alcohol and paracetamol. <i>Australian Prescriber</i> , 2004, 27, 14-15.	0.5	13

#	ARTICLE	IF	CITATIONS
253	Aspects of the clinical pharmacology of non-steroidal anti-inflammatory drugs. <i>Clinics in Rheumatic Diseases</i> , 1984, 10, 229-49.	1.2	13
254	Optimising computerised alerts within electronic medication management systems: A synthesis of four years of research. <i>Studies in Health Technology and Informatics</i> , 2014, 204, 1-6.	0.2	13
255	The effect of concurrent aspirin upon plasma concentrations of tenoxicam.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 455-462.	1.1	12
256	Compliance with Criteria Necessary for Effective Drug Concentration Monitoring. <i>Therapeutic Drug Monitoring</i> , 1990, 12, 250-257.	1.0	12
257	Cyclosporin and calcium channel blockers: an exploitable drug interaction?. <i>Medical Journal of Australia</i> , 1992, 157, 296-297.	0.8	12
258	Hazards of low dose methotrexate. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 670-673.	0.5	12
259	Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. <i>Climacteric</i> , 2003, 6, 104-111.	1.1	12
260	Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?. <i>Internal Medicine Journal</i> , 2006, 36, 19-27.	0.5	12
261	Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. <i>Medical Journal of Australia</i> , 2007, 187, 160-163.	0.8	12
262	Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2363-2368.	1.2	12
263	Febuxostat-associated rhabdomyolysis in chronic renal failure. <i>Medical Journal of Australia</i> , 2015, 203, 107-108.	0.8	12
264	Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration. <i>American Journal of Kidney Diseases</i> , 2016, 68, 990-992.	2.1	12
265	The safety and pharmacokinetics of metformin in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 565-575.	1.9	12
266	Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review. <i>Transplantation Reviews</i> , 2021, 35, 100610.	1.2	12
267	Prevalence and determinants of inappropriate antibiotic dispensing at private drug retail outlets in urban and rural areas of Indonesia: a mixed methods study. <i>BMJ Global Health</i> , 2021, 6, e004993.	2.0	12
268	mHealth App Patient Testing and Review of Educational Materials Designed for Self-Management of Gout Patients: Descriptive Qualitative Studies. <i>JMIR MHealth and UHealth</i> , 2018, 6, e182.	1.8	12
269	Community pharmacies, drug stores, and antibiotic dispensing in Indonesia: a qualitative study. <i>BMC Public Health</i> , 2021, 21, 1800.	1.2	12
270	Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3114-3131.	1.1	12

#	ARTICLE	IF	CITATIONS
271	Effects of exercise performance on drugs used in musculoskeletal disorders. <i>Medicine and Science in Sports and Exercise</i> , 1981, 13, 272-275.	0.2	11
272	Clinical response to non-steroidal anti-inflammatory drugs in urate-crystal induced inflammation: a simultaneous study of intersubject and intrasubject variability. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 341-347.	1.1	11
273	Evidence and desperation in off-label prescribing: recombinant factor VIIa. <i>BMJ: British Medical Journal</i> , 2012, 344, d7926-d7926.	2.4	11
274	Comparing dose prediction software used to manage gentamicin dosing. <i>Internal Medicine Journal</i> , 2013, 43, 519-525.	0.5	11
275	Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approach. <i>International Journal of Medical Informatics</i> , 2015, 84, 595-600.	1.6	11
276	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2772-2783.	1.1	11
277	Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 726-731.	1.0	11
278	Trends, determinants and differences in antibiotic use in 68 residential aged care homes in Australia, 2014-2017: a longitudinal analysis of electronic health record data. <i>BMC Health Services Research</i> , 2020, 20, 883.	0.9	11
279	Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4273-4282.	1.1	11
280	Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. <i>Internal Medicine Journal</i> , 2022, 52, 1135-1143.	0.5	11
281	Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?. <i>Internal Medicine Journal</i> , 2007, 37, 601-606.	0.5	10
282	Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study. <i>Clinical Therapeutics</i> , 2010, 32, 1329-1342.	1.1	10
283	The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 685-691.	2.3	10
284	No evidence or no alternative? Taking responsibility for off-label prescribing. <i>Internal Medicine Journal</i> , 2012, 42, 247-251.	0.5	10
285	HLA-B*5801 Should Be Used to Screen for Risk of Stevens-Johnson Syndrome in Family Members of Han Chinese Patients Commencing Allopurinol Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 96.2-97.	1.0	10
286	Evaluation of Hospital-Wide Computerised Decision Support in an Intensive Care Unit: An Observational Study. <i>Anaesthesia and Intensive Care</i> , 2016, 44, 507-512.	0.2	10
287	Education to improve vancomycin use: the perspectives of educators and education recipients. <i>Internal Medicine Journal</i> , 2020, 50, 565-572.	0.5	10
288	Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1981-1984.	1.3	10

#	ARTICLE	IF	CITATIONS
289	Co-designing a dashboard of predictive analytics and decision support to drive care quality and client outcomes in aged care: a mixed-method study protocol. <i>BMJ Open</i> , 2021, 11, e048657.	0.8	10
290	Can we deny patients expensive drugs?. <i>Australian Prescriber</i> , 2006, 29, 146-148.	0.5	10
291	Variability in Response to NSAID. , 1985, 17, 15-19.		10
292	Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 1988, 9, 273-283.	1.1	9
293	Pharmaceutical company promotion: striking a balance. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 291-293.	0.5	9
294	Targeted Pharmacotherapy of Evoked Phenomena in Neuropathic Pain: A Review of the Current Evidence. <i>Pain Medicine</i> , 2007, 8, 48-64.	0.9	9
295	Hyperuricemia, Cardiovascular Disease, and the Metabolic Syndrome: Figure 1.. <i>Journal of Rheumatology</i> , 2009, 36, 2842.2-2843.	1.0	9
296	Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?. <i>Medical Journal of Australia</i> , 2011, 194, 567-568.	0.8	9
297	OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol. <i>BMJ Open</i> , 2016, 6, e011278.	0.8	9
298	Dealing with the spiralling price of medicines: issues and solutions. <i>Internal Medicine Journal</i> , 2018, 48, 16-24.	0.5	9
299	Reliability, ease of use and usefulness of I-MeDeSA for evaluating drug-drug interaction alerts in an Australian context. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 83.	1.5	9
300	Optimising computerised decision support to transform medication safety and reduce prescriber burden: study protocol for a mixed-methods evaluation of drug-drug interaction alerts. <i>BMJ Open</i> , 2019, 9, e026034.	0.8	9
301	Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. <i>BMJ Open</i> , 2017, 7, e017281.	0.8	9
302	Identification of strategies to reduce computerized alerts in an electronic prescribing system using a Delphi approach. <i>Studies in Health Technology and Informatics</i> , 2013, 192, 8-12.	0.2	9
303	12. Toxicity of antirheumatic drugs. <i>Medical Journal of Australia</i> , 1997, 166, 378-383.	0.8	8
304	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. <i>HIV Clinical Trials</i> , 2004, 5, 91-98.	2.0	8
305	Drug and therapeutics committees "are they fulfilling their potential to improve the quality use of medicines?. <i>International Journal of Pharmacy Practice</i> , 2010, 11, 175-181.	0.3	8
306	The pharmacokinetics of metformin and concentrations of haemoglobin A_{1C} and lactate in indigenous and non-indigenous Australians with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 617-623.	1.1	8

#	ARTICLE	IF	CITATIONS
307	Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network. <i>Internal Medicine Journal</i> , 2020, 50, 17-23.	0.5	8
308	Efficacy and harms of orally, intramuscularly or intravenously administered glucocorticoids for sciatica: A systematic review and meta-analysis. <i>European Journal of Pain</i> , 2020, 24, 518-535.	1.4	8
309	Better outcomes for patients with gout. <i>Inflammopharmacology</i> , 2020, 28, 1395-1400.	1.9	8
310	Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 245-251.	1.0	8
311	The Contribution of Enantiomers to Variability in Response to Anti-Inflammatory Drugs. , 1988, 24, 76-84.		8
312	Adherence to Urate-Lowering Therapy. <i>Southern Medical Journal</i> , 2009, 102, 114-115.	0.3	8
313	Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?. <i>Medical Journal of Australia</i> , 1993, 159, 182-4.	0.8	8
314	Antimalarials in Rheumatic Diseases. <i>Australian and New Zealand Journal of Medicine</i> , 1982, 12, 645-649.	0.5	7
315	1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 238-241.	1.1	7
316	Anti-rheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994. <i>Rheumatology</i> , 1997, 36, 487-490.	0.9	7
317	1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 197-200.	1.1	7
318	Patterns of Analgesic Prescribing for Patients with Chronic Non-Malignant Pain in NSW. <i>Journal of Pharmacy Practice and Research</i> , 1998, 28, 83-88.	0.2	7
319	Stereoselective disposition of ibuprofen enantiomers in man. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, S759-S764.	1.1	7
320	Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies. <i>Journal of Bioethical Inquiry</i> , 2006, 3, 139-148.	0.9	7
321	The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 26.	2.2	7
322	Access to high cost medicines in Australia: ethical perspectives. <i>Australia and New Zealand Health Policy</i> , 2008, 5, 4.	2.2	7
323	Are specialist physicians missing out on the e-Health boat?. <i>Internal Medicine Journal</i> , 2009, 39, 655-661.	0.5	7
324	Successful use of allopurinol in a patient on dialysis. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125814-bcr0220125814.	0.2	7

#	ARTICLE	IF	CITATIONS
325	Understanding Compliance to an Antibiotic Prescribing Policy: Perspectives of Policymakers and Prescribers. <i>Journal of Pharmacy Practice and Research</i> , 2013, 43, 32-36.	0.5	7
326	Overcoming Entrenched Disagreements: the Case of Misoprostol for Postpartum Haemorrhage. <i>Developing World Bioethics</i> , 2015, 15, 48-54.	0.6	7
327	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: cardiovascular and renal benefits in patients with chronic kidney disease. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1481-1490.	0.8	7
328	Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1126-1127, 121764.	1.2	7
329	Australian patient perspectives on the impact of gout. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1372-1378.	0.9	7
330	Out-of-pocket spending among a cohort of Australians living with gout. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 327-334.	0.9	7
331	Tolerability of Paracetamol*. <i>Drugs</i> , 2003, 63, 39-42.	4.9	7
332	Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
333	Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4894-4901.	1.1	7
334	EFFECTS OF VARIOUS DRUGS ON THE OSMOTIC LYSIS OF RAT MAST CELLS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1978, 5, 477-485.	0.9	6
335	Interaction of salicylate and corticosteroids in man.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 334-337.	1.1	6
336	Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. <i>Agents and Actions</i> , 1991, 34, 381-386.	0.7	6
337	Towards the safer use of non-steroidal anti-inflammatory drugs. <i>Journal of Quality in Clinical Practice</i> , 1999, 19, 51-53.	0.5	6
338	Perspectives on Drug and Therapeutics Committee policy implementation. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 526-545.	1.5	6
339	Recent developments in targeting access to high cost medicines in Australia. <i>Australia and New Zealand Health Policy</i> , 2005, 2, 28.	2.2	6
340	Accessing health outcome data on high-cost medicines in Australia. <i>Medical Journal of Australia</i> , 2006, 184, 411-413.	0.8	6
341	Do ethical Guidelines make a difference to decision-making?. <i>Internal Medicine Journal</i> , 2009, 39, 800-805.	0.5	6
342	What's in a name? Brand name confusion and generic medicines. <i>Medical Journal of Australia</i> , 2011, 195, 650-651.	0.8	6

#	ARTICLE	IF	CITATIONS
343	Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency. <i>Medical Journal of Australia</i> , 2012, 197, 204-205.	0.8	6
344	Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII. <i>Hastings Center Report</i> , 2014, 44, 38-45.	0.7	6
345	Severe GHB withdrawal delirium managed with dexmedetomidine. <i>Medical Journal of Australia</i> , 2016, 205, 251-252.	0.8	6
346	<i>STANDING Collaboration</i>: a study protocol for developing clinical standards. <i>BMJ Open</i> , 2017, 7, e014048.	0.8	6
347	Do user preferences align with human factors assessment scores of drugâ€“drug interaction alerts?. <i>Health Informatics Journal</i> , 2020, 26, 563-575.	1.1	6
348	A profile of health status and demographics of aged care facility residents with gout. <i>Australasian Journal on Ageing</i> , 2020, 39, e153-e161.	0.4	6
349	Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1422-1431.	1.1	6
350	Non-steroidal Anti-inflammatory Drugs. , 2013, , 1-9.		6
351	Variability in response to NSAIDs: what progress?. <i>Agents and Actions Supplements</i> , 1993, 44, 3-6.	0.2	6
352	Clinical Pharmacology and Efficacy of Benorylate in Patients with Rheumatoid Arthritis. <i>Australian and New Zealand Journal of Medicine</i> , 1978, 8, 22-28.	0.5	5
353	Formation of methyl ester of salicylic acid during quantitation of salicylic acid in urine by high-pressure liquid chromatography. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 1090-1092.	1.6	5
354	Classification of Overdose/Self-Poisoning Presentations to an Accident and Emergency Department. <i>Substance Use and Misuse</i> , 1987, 22, 941-955.	0.6	5
355	Suitability of Reverse-Phase Columns from Different Sources for Separation of Uric Acid from Its Oxidation Products. <i>Analytical Biochemistry</i> , 1993, 210, 428-430.	1.1	5
356	Improving Decision Outcomes of Drug and Therapeutics Committees. <i>Journal of Pharmacy Practice and Research</i> , 2003, 33, 65-67.	0.5	5
357	Protocol for the Quick Clinical study; a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice. <i>BMC Medical Informatics and Decision Making</i> , 2006, 6, 33.	1.5	5
358	Utility of urine drug screening: A Clinical audit. <i>EMA - Emergency Medicine Australasia</i> , 2007, 19, 246-252.	0.5	5
359	Death and morbidity from supratherapeutic dosing of colchicine. <i>Medical Journal of Australia</i> , 2011, 194, 612-613.	0.8	5
360	Implementation of Revised Aminoglycoside Guidelines: Australian Hospitals â€“Left in the Lurchâ€™. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 178-179.	0.5	5

#	ARTICLE	IF	CITATIONS
361	Pneumonia Severity Scores and Prescribing Antibiotics for Community-Acquired Pneumonia at an Australian Hospital. <i>Journal of Pharmacy Practice and Research</i> , 2013, 43, 97-100.	0.5	5
362	Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. <i>Current Rheumatology Reports</i> , 2018, 20, 47.	2.1	5
363	Management of gout in older people. <i>Journal of Pharmacy Practice and Research</i> , 2019, 49, 90-97.	0.5	5
364	Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 879-888.	0.8	5
365	Usability of Reports Generated by a Computerised Dose Prediction Software. <i>Studies in Health Technology and Informatics</i> , 2018, 252, 27-32.	0.2	5
366	Influence of flufenamic acid and calcium ion concentration on the histamine release from rat mast cells induced by compound 48/80 and the calcium ionophore A23187. <i>Biochemical Pharmacology</i> , 1978, 27, 1385-1387.	2.0	4
367	COX-2 Specific Inhibitors and the Hospital Pharmacist. <i>Journal of Pharmacy Practice and Research</i> , 2000, 30, 41-43.	0.2	4
368	Promoting Rational Prescribing by Emergency Department Junior Medical Officers. <i>Journal of Pharmacy Practice and Research</i> , 2000, 30, 262-267.	0.2	4
369	COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred. <i>Arthritis Research</i> , 2003, 5, 116.	2.0	4
370	Sample size is beside the point in policy development research. <i>Australian and New Zealand Journal of Public Health</i> , 2005, 29, 583.	0.8	4
371	Pethidine in emergency departments: promoting evidence-based prescribing. <i>Medical Journal of Australia</i> , 2006, 184, 44-45.	0.8	4
372	Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 380-381.	1.1	4
373	Beyond Rhetoric in Debates About the Ethics of Marketing Prescription Medicines to Consumers: The Importance of Vulnerability in People, Situations, and Relationships. <i>American Journal of Bioethics Primary Research</i> , 2010, 1, 11-21.	1.5	4
374	Enhanced elimination of phenobarbital using charcoal haemoperfusion in a patient with severe poisoning. <i>British Journal of Anaesthesia</i> , 2011, 107, 820-821.	1.5	4
375	Why is disulfiram not on the PBS?. <i>Medical Journal of Australia</i> , 2011, 195, 371-372.	0.8	4
376	Rofecoxib and Clinically Significant Gastrointestinal Events. <i>American Journal of the Medical Sciences</i> , 2011, 342, 438-439.	0.4	4
377	Formulating an Ethics Agenda for Drug Development, Regulation, and Utilization. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 46-49.	0.8	4
378	Pharmacometrics: an underused resource in Australian clinical research. <i>Medical Journal of Australia</i> , 2014, 200, 82-83.	0.8	4

#	ARTICLE	IF	CITATIONS
379	Understanding and improving the use of allopurinol in a teaching hospital. Internal Medicine Journal, 2015, 45, 383-390.	0.5	4
380	PRECISE " pregabalin in addition to usual care: statistical analysis plan. Trials, 2016, 17, 53.	0.7	4
381	Exploring sub-optimal use of an electronic risk assessment tool for venous thromboembolism. Applied Ergonomics, 2016, 55, 63-69.	1.7	4
382	An experimental investigation of the impact of alert frequency and relevance on alert dwell time. International Journal of Medical Informatics, 2020, 133, 104027.	1.6	4
383	A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. British Journal of Clinical Pharmacology, 2020, 86, 2486-2496.	1.1	4
384	A Tool for Evaluating Medication Alerting Systems: Development and Initial Assessment. JMIR Medical Informatics, 2021, 9, e24022.	1.3	4
385	Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?. Medical Journal of Australia, 2004, 181, 457; discussion 457-8.	0.8	4
386	A User-Centred Approach to Designing an eTool for Gout Management. Studies in Health Technology and Informatics, 2016, 227, 28-33.	0.2	4
387	THE EFFECT OF VARIOUS DRUGS ON ADENOSINE TRIPHOSPHATE CONTENT AND HISTAMINE RELEASE FROM RAT PERITONEAL CELL SUSPENSIONS RICH IN MAST CELLS. Clinical and Experimental Pharmacology and Physiology, 1978, 5, 223-227.	0.9	3
388	Aminophylline in the Emergency Department. Chest, 1991, 100, 1572-1577.	0.4	3
389	NAILFOLD CAPILLARY CIRCULATION IN OSTEOARTHRITIS. Rheumatology, 1993, 32, 1062-1065.	0.9	3
390	Pharmaceutical Health and Rational Use of Medicines Committee. Journal of Pharmacy Practice and Research, 2003, 33, 87-89.	0.5	3
391	Paracetamol should be first-line therapy in osteoarthritis. Medical Journal of Australia, 2005, 182, 198-199.	0.8	3
392	Wrong Questions, Wrong Answers? Are We Getting the Drugs We Need?. Clinical Pharmacology and Therapeutics, 2012, 91, 367-369.	2.3	3
393	Oxypurinol, allopurinol and allopurinol-ribose in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease. British Journal of Clinical Pharmacology, 2012, 73, 828-829.	1.1	3
394	The management of severe hypertension in Australian general practice. BMC Health Services Research, 2013, 13, 414.	0.9	3
395	Multiple episodes of aspirin overdose in an individual patient: a case report. Journal of Medical Case Reports, 2014, 8, 374.	0.4	3
396	The Impact of Ribavirin Plasma Concentration on the Efficacy of the Interferon-Sparing Regimen, Sofosbuvir and Ribavirin. Antiviral Therapy, 2016, 21, 127-132.	0.6	3

#	ARTICLE	IF	CITATIONS
397	Comparative efficacy trials with no placebo group cannot determine efficacy. <i>BMJ, The</i> , 2015, 350, h3292-h3292.	3.0	3
398	Allopurinol dose relative to renal function and risk of hypersensitivity reactions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e21-e21.	0.5	3
399	Trends in metformin utilisation and dose appropriateness in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1489-1496.	0.8	3
400	Improving adherence to urate-lowering therapy in people living with gout. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 542-544.	0.9	3
401	Does splitting a tablet obtain the accurate dose?. <i>Medicine (United States)</i> , 2019, 98, e17189.	0.4	3
402	OASISâ€”a randomised, placebo-controlled trial of oral glucocorticoids for leg pain in patients with acute sciatica: trial protocol. <i>BMJ Open</i> , 2020, 10, e040559.	0.8	3
403	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1019-1028.	1.6	3
404	Tacrolimus Therapy in Adult Heart Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, 736-746.	1.0	3
405	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
406	Understanding doctors' perceptions of their prescribing competency and the value they ascribe to an electronic prescribing system. <i>Studies in Health Technology and Informatics</i> , 2012, 178, 1-6.	0.2	3
407	OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal painâ€”a statistical analysis plan. <i>Trials</i> , 2022, 23, 212.	0.7	3
408	Mandatory Medication Indications in Electronic Systems - The Prescriber Perspective. <i>Studies in Health Technology and Informatics</i> , 2019, 265, 95-100.	0.2	3
409	Australian hospital outpatient pharmacies: service adaptations during the 2020 national coronavirus disease 2019 lockdown. <i>Journal of Pharmacy Practice and Research</i> , 2022, 52, 326-328.	0.5	3
410	The measurement of histamine release from suspensions of rat peritoneal cells rich in mast cells. <i>Agents and Actions</i> , 1977, 7, 431-436.	0.7	2
411	Effect of aspirin on ulcer site blood flow in cat stomachs. <i>American Journal of Physiology - Renal Physiology</i> , 1992, 263, G155-G160.	1.6	2
412	Interpretation of chloroquine pharmacokinetic data. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 407-408.	0.8	2
413	Inflammation '93. <i>Agents and Actions</i> , 1994, 41, C145-C149.	0.7	2
414	Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 79-81.	1.1	2

#	ARTICLE	IF	CITATIONS
415	Pharmacotherapeutics: what a difference five decades makes!. Medical Journal of Australia, 2001, 174, 48-51.	0.8	2
416	Stakeholder Opinions on the Implementation of Drug and Therapeutics Committee Decisions. Journal of Pharmacy Practice and Research, 2004, 34, 178-182.	0.5	2
417	Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. International Journal of Rheumatic Diseases, 2008, 11, 11-14.	0.9	2
418	Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Internal Medicine Journal, 2011, 41, 314-320.	0.5	2
419	Consistency or efficiency? A dilemma for designers. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 1119.2-1120.	2.2	2
420	Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine. Clinical Rheumatology, 2016, 35, 2375-2376.	1.0	2
421	Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendations. EMA - Emergency Medicine Australasia, 2019, 31, 1053-1058.	0.5	2
422	Predictors of Success in Gout Treatment. Journal of Rheumatology, 2020, 47, 313-315.	1.0	2
423	Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?. Therapeutic Innovation and Regulatory Science, 2021, 55, 138-141.	0.8	2
424	How to make the most of a visit from a pharmaceutical company representative. Australian Prescriber, 2000, 23, 97-99.	0.5	2
425	Factors affecting prescribing in general practice – a role play[*]. Medical Journal of Australia, 1992, 157, 621-622.	0.8	2
426	Targeting neurotrophic factors for low back pain and sciatica: a systematic review and meta-analysis. Rheumatology, 2022, 61, 2243-2254.	0.9	2
427	Prescribersâ€™ reported acceptance and use of drug-drug interaction alerts: An Australian survey. Health Informatics Journal, 2022, 28, 146045822211006.	1.1	2
428	Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout. British Journal of Clinical Pharmacology, 2022, 88, 5359-5368.	1.1	2
429	DEAFNESS DUE TO ASPIRIN. Journal of Clinical Pharmacology, 1979, 19, 328-328.	1.0	1
430	Pharmaceutical Benefits Scheme: Rapid Change and Impetus towards Achieving QUM. Journal of Pharmacy Practice and Research, 2007, 37, 4-6.	0.5	1
431	Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda. Medical Journal of Australia, 2012, 196, 374-375.	0.8	1
432	Hypouricemic Effects of Prednisone and Allopurinol: An Uneven Playing Field?. Canadian Journal of Cardiology, 2014, 30, 376.e1.	0.8	1

#	ARTICLE	IF	CITATIONS
433	A review of strategies to improve rational prescribing in asthma. <i>Journal of Pharmacy Practice and Research</i> , 2014, 44, 195-200.	0.5	1
434	Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy. <i>Australian Health Review</i> , 2014, 38, 160.	0.5	1
435	The Ethics Around Drug Labels and Generic Medicines. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 348-351.	0.8	1
436	Prednisone for Cardiac Failure in Patients with Hypertension. <i>Journal of Rheumatology</i> , 2015, 42, 739-740.	1.0	1
437	Efficacy and safety of paracetamol compared to placebo for knee and hip osteoarthritis: A cochrane systematic review. <i>Osteoarthritis and Cartilage</i> , 2016, 24, S44.	0.6	1
438	Addendum Regarding "Pharmacokinetics of Metformin in Patients Receiving Regular Hemodialysis" (<i>Am J Kidney Dis</i> . 2016;68[6]:990-992). <i>American Journal of Kidney Diseases</i> , 2017, 69, 870-871.	2.1	1
439	Could metformin be used in patients with advanced chronic kidney disease?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 302-303.	2.2	1
440	Is it ethical to prescribe paracetamol for acute low back pain and osteoarthritis?. <i>Lancet Rheumatology</i> , The, 2019, 1, e140-e142.	2.2	1
441	Effect of dose administration aids on adherence to self-administered medications: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e030536.	0.8	1
442	"Some sort of fantasy land": A qualitative investigation of appropriate prescribing in cancer care. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 747-754.	0.9	1
443	Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes. <i>Internal Medicine Journal</i> , 2020, 50, 645-646.	0.5	1
444	Indications-based prescribing: A challenge for hospital prescribers. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 730-731.	1.1	1
445	Expanding the role of Australian community dietitians in gout management. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1402-1408.	0.9	1
446	Rethinking the discordance between guidelines and practice in rheumatoid arthritis treatment. <i>Medical Journal of Australia</i> , 2011, 195, 446-447.	0.8	1
447	Therapeutic Considerations from Pharmacokinetics and Metabolism: Ibuprofen and Paracetamol. , 1998, , 77-92.		1
448	Non-steroidal Anti-inflammatory Drugs: Overview. , 2016, , 986-993.		1
449	Sodium-glucose cotransporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction. <i>Internal Medicine Journal</i> , 2022, , .	0.5	1
450	The response to COVID-19 among drug retail outlets in Indonesia: A cross-sectional survey of knowledge, attitudes, and practices. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 22, 100420.	1.3	1

#	ARTICLE	IF	CITATIONS
451	A comparison of the efficacy of L-ketobutyric acid (KBA), nordihydro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns ¹ . <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 122-122.	2.3	0
452	WEIGHT MAINTENANCE IN HOSPITALIZED GERIATRIC PATIENTS TREATED WITH BETA-BLOCKERS. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1125-1126.	1.3	0
453	India: Emerging Centre of Drug Development. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 262-264.	0.5	0
454	Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 709-713.	0.8	0
455	Death of the "Blockbuster"™ and "Pivotal"™ Clinical Trial: Rethinking the Drug Development Process. <i>Journal of Pharmacy Practice and Research</i> , 2011, 41, 94-96.	0.5	0
456	An Audit of a Therapeutic Drug Monitoring Service for Allopurinol Therapy. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 863-866.	1.0	0
457	Response to A. G. Helg's comments on the LEGS study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e41-e41.	0.5	0
458	Clinical predictors of medial knee osteoarthritis progression over 2 years. <i>Osteoarthritis and Cartilage</i> , 2016, 24, S220.	0.6	0
459	Introduction to the Special Section: Phase I Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 274-275.	0.8	0
460	Lactic Acidosis, Metformin Use, and Dose-Response Association. <i>JAMA Internal Medicine</i> , 2018, 178, 1428.	2.6	0
461	Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM). <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1327-1332.	0.8	0
462	Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531983688.	1.2	0
463	Off-label quetiapine prescribing in general hospital inpatients: an Australian experience. <i>Journal of Pharmacy Practice and Research</i> , 2020, 50, 316-320.	0.5	0
464	Healthcare expenditure and its predictors in a cohort of Australians living with sciatica. <i>European Spine Journal</i> , 2021, 30, 878-885.	1.0	0
465	Honorary Professor Garry Graham. <i>Inflammopharmacology</i> , 2021, 29, 1255-1259.	1.9	0
466	Letters to the Editor: Fenofibrate-warfarin interaction. <i>Australian Prescriber</i> , 2007, 30, 32-34.	0.5	0
467	C15 Disease-modifying antirheumatic drugs. , 2011, , 585-619.		0
468	Salicylates. , 2013, , 1-6.		0

#	ARTICLE	IF	CITATIONS
469	Antimalarial Drugs. , 2013, , 1-6.		0
470	Antimalarial Drugs. , 2016, , 97-101.		0
471	Salicylates. , 2016, , 1169-1174.		0
472	Disease-Modifying Anti-rheumatic Drugs. , 2019, , 709-750.		0
473	Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric, 2003, 6, 104-111.	1.1	0
474	Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspective. Clinical and Experimental Rheumatology, 2001, 19, S59-62.	0.4	0